Skip to main content

Branded

  • Chrono Therapeutics shares clinicals supporting wearable smoking cessation device

    CHICAGO - Chrono Therapeutics on Friday announced that clinical data for the company's smoking cessation technology showed a statistically significant reduction in nicotine cravings in a trial of adult male smokers. The data were presented at the Society for Research on Nicotine & Tobacco's 22nd Annual Meeting.
     
  • FDA approves expanded Imbruvica indication

    SILVER SPRING, Md. — The Food and Drug Administration has approved a new indication for Janssen Biotech’s and Pharmacyclics’ Imbruvica (ibrutinib) capsules, the companies announced Friday.
     
  • Syncing monthly prescription refills to boost adherence, outcomes

    With medication nonadherence leading to enormous health complications for millions of Americans — and generating staggering and needless cost spikes that add as much as $290 billion a year to the nation’s healthcare costs — the search for ways to get patients to take their prescription medicines as directed has become increasingly urgent.

  • Flu levels remain high across southern and western U.S., Walgreens Flu Index finds

    DEERFIELD, Ill. - The level of flu continues to be high across Arizona, Texas and Mississippi, according to the lateset Walgreens Flu Index released Thursday. Looking forward, for the week of Feb. 28 the top three states experiencing the greatest flu activity gains included Mississippi, Kentucky and South Carolina. 
     
    The Walgreens Flu Index does not provide data measuring actual levels or severity of flu activity, but rather, illustrates which populations are experiencing the most incidences each week based on Index methodology.
  • FDA approves Gilead’s Odefsey

    SILVER SPRING, Md. — The Food and Drug Administration has approved Gilead Sciences’ new drug Odefsey (emtricitabine 200 mg/rilpivirine 25 mg/tenofovir alafenamide 25 mg), the company announced Tuesday. 
     
  • NACDS urges collaboration between regulators, law enforcement in letter to Senate

    ARLINGTON, Va. - In a letter sent to members of the U.S. Senate on Monday, the National Association of Chain Drug Stores urged passage of legislation that would spur collaboration among health and enforcement authorities for drug abuse solutions that maintain patients’ legitimate access to medications. 
     
  • FDA grants new indication for Novartis’ Afinitor

    SILVER SPRING, Md. — The Food and Drug Administration has granted Novartis’ Afinitor (everolimus) tablets a new indication after giving it a priority review designation. The drug can now be prescribed to treat adults with unresectable, locally advanced of metastatic progressive, well-differentiated nonfunctional neuroendocrine tumors (NET) with lung or gastrointestinal origin.
     
X
This ad will auto-close in 10 seconds